CD4 News and Research

RSS

CD4 tests can reduce costs, extend lives of HIV-positive people in Africa

"Cost-Effectiveness of HIV Monitoring Strategies in Resource-Limited Settings," Archives of Internal Medicine: The use of a CD4 test could help reduce costs and extend the lives of HIV-positive people in Southern Africa, according to a study conducted by researchers at Stanford University's School of Medicine and the Palo Alto Veterans Affairs Health Care System.

24 Sep 2008

Thai health experts call for review of prevention of mother-to-child HIV transmission program

Health experts in Thailand are calling for a review of the country's national program to prevent mother-to-child HIV transmission, which follows World Health Organization guidelines, the Bangkok Post reports.

24 Sep 2008

Early antiretroviral treatment for people with HIV/TB coinfection could reduce mortality by half

People with HIV/tuberculosis coinfection who began antiretroviral treatment within six months of starting TB treatment had a 55% lower mortality rate than people with HIV/TB coinfection who did not begin antiretroviral therapy until after they had finished a six-month TB treatment course, according to a study conducted by researchers at the University of KwaZulu-Natal, Business Day reports (Kahn, Business Day, 9/18).

22 Sep 2008

Second phase of TB program that integrates HIV treatment begins in Harare, Zimbabwe

The second phase of the Integrated Health Care program to control tuberculosis has been implemented in Zimbabwe's capital of Harare, the Herald reports.

10 Sep 2008

Discovery of gene that could help develop HIV/AIDS vaccine

In an article published in the journal Science on Thursday, researchers announced that they have discovered a gene, called Apobec3, that might help in the development of an HIV/AIDS vaccine, Reuters Health reports.

9 Sep 2008

Anadis to commercialise "BioGard" adjunctive therapy for HIV/AIDS

Anadis announced today its commercialization of a new product, BioGard, intended to maintain gastrointestinal and immune system health. The specific formulation may be of particular clinical benefit in persons undergoing antiretroviral therapy for HIV/AIDS.

4 Sep 2008

Highly active antiretroviral therapy might increase risk of asthma in young children

Highly active antiretroviral therapy might increase the risk of asthma among children because of the therapy's effect on the immune system and CD4+ T cell levels, according to a study recently published in the Journal of Allergy and Clinical Immunology, Reuters reports.

29 Aug 2008

Early trigger for type-1 diabetes found in mice

Scientists at the Stanford University School of Medicine are shedding light on how type-1 diabetes begins.

26 Aug 2008

Bionor Immuno trials new innovative therapeutic immunization designed to help existing HIV and AIDS patients

Bionor Immuno today announced that it has advanced its efforts to develop the first HIV therapeutic immunization with the dosing of patients in a global Phase 2b clinical trial of the company's lead candidate (Vacc-4x).

4 Aug 2008

Update of treatment guidelines for HIV infection recommended by experts

An evaluation of the latest information on the treatment of the adult human immunodeficiency virus (HIV) has led an international panel of experts to update the guidelines and recommendations for antiretroviral treatment of HIV.

3 Aug 2008

Researchers disprove long-standing belief about HIV treatment

Researchers at Wake Forest University Baptist Medical Center have disproved a long-standing clinical belief that the hepatitis C virus slows or stunts the immune system's ability to restore itself after HIV patients are treated with a combination of drugs known as the 'cocktail.'

27 Jul 2008

Life expectancy of HIV patients increases

HIV-infected patients in high income countries are living some 13 years longer thanks to improvements in combination antiretroval therapy (cART), according to new research by the University of Bristol published in a HIV Special Issue of The Lancet today.

24 Jul 2008

HIV-I damages the immune system early than originally thought

New research into the earliest events occurring immediately upon infection with HIV-I shows that the virus deals a stunning blow to the immune system earlier than was previously understood. According to scientists at Duke University Medical Center, this suggests the window of opportunity for successful intervention may be only a matter of days - not weeks - after transmission, as researchers had previously believed.

19 Jul 2008

Tired B cells hamper immune response to HIV

Recent studies have shown that HIV causes a vigorous and prolonged immune response that eventually leads to the exhaustion of key immune system cells--CD4+ and CD8+ T-cells--that target HIV.

14 Jul 2008

FDA approves Energex Systems non-drug therapy for HIV research

Energex Systems, Inc. announced today that it has been granted approval from the Federal Food and Drug Administration (FDA) to utilize its experimental HemoModulation therapy in a clinical trial of HIV infected patients. The purpose of the study will be to demonstrate safety and monitor viral load changes in patients who are not yet eligible for antiviral drug therapy.

14 Jul 2008

Discover of key patterns in gene packaging

Although every cell of our bodies contains the same genetic instructions, specific genes typically act only in specific cells at particular times. Other genes are "silenced" in a variety of ways. One mode of gene silencing depends upon the way DNA, the genetic material, is packed in the nucleus of cells.

13 Jul 2008

Asthma risk increases in children treated for HIV

Children whose immune systems rebound after treatment with potent anti-viral drugs for HIV infection face an increased risk of developing asthma, said a federally funded consortium of researchers led by those from Baylor College of Medicine in a report that appears online in the Journal of Allergy and Clinical Immunology.

1 Jul 2008

Yeast-based vaccine induces immune responses and reduces tumor size in mice

Scientists have found that vaccination with a heat-killed, non-toxic yeast that is genetically engineered to manufacture a common tumor protein can induce specific and repeated anti-tumor immune responses in mice.

1 Jul 2008

Zinc finger technology brings personalized HIV therapy a step closer

Researchers at the University of Pennsylvania School of Medicine and collaborators are using minute, naturally occurring proteins called zinc fingers to engineer T cells to one day treat AIDS in humans.

30 Jun 2008

Patient's own infection-fighting T cells put late-stage melanoma into long-term remission

Researchers describe the first successful use of a human patient's cloned infection-fighting T cells as the sole therapy to put an advanced solid-tumor cancer into long-term remission. A team led by Cassian Yee, M.D., an associate member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, reports these findings in the June 19 issue of the New England Journal of Medicine.

19 Jun 2008